Related Experiment Video
Updated: Apr 27, 2026
Evaluation of T Follicular Helper Cells and Germinal Center Response During Influenza A Virus Infection in Mice
Published on: June 27, 2020
Deferoxamine compensates for decreases in B cell counts and reduces mortality in enterovirus 71-infected mice
Yajun Yang1, Jing Ma2, Jinghui Xiu3
1Key Laboratory of Human Diseases Comparative Medicine, Ministry of Health, Institute of Laboratory Animal Science, CAMS & Comparative Medicine Centre, Peking Union Medical College, Beijing 100021, China. yangyajun484@hotmail.com.
Abstract:
Enterovirus 71 is one of the major causative agents of hand, foot and mouth disease in children under six years of age. No vaccine or antiviral therapy is currently available. In this work, we found that the number of B cells was reduced in enterovirus 71-infected mice. Deferoxamine, a marine microbial natural product, compensated for the decreased levels of B cells caused by enterovirus 71 infection. The neutralizing antibody titer was also improved after deferoxamine treatment. Furthermore, deferoxamine relieved symptoms and reduced mortality and muscle damage caused by enterovirus 71 infection. This work suggested that deferoxamine has the potential for further development as a B cell-immunomodulator against enterovirus 71.
Insights
Deferoxamine treatment improved B cell levels and antibody responses in mice infected with Enterovirus 71 (EV71), reducing disease severity and mortality. This suggests potential for EV71 therapy.
Area of Science:
- Virology
- Immunology
- Pharmacology
Background:
- Enterovirus 71 (EV71) is a primary cause of hand, foot, and mouth disease in young children.
- Current treatment options for EV71 infection are limited, with no available vaccines or antiviral therapies.
Purpose of the Study:
- To investigate the therapeutic potential of deferoxamine against EV71 infection.
- To evaluate deferoxamine's effects on B cell levels, antibody production, and clinical outcomes in an EV71 mouse model.
Main Methods:
- EV71 infection was induced in mice.
- Deferoxamine treatment was administered to infected mice.
- B cell counts, neutralizing antibody titers, clinical symptoms, mortality, and muscle damage were assessed.
Main Results:
- EV71 infection led to a reduction in B cell numbers.
- Deferoxamine treatment restored B cell levels and increased neutralizing antibody titers.
- Deferoxamine administration alleviated EV71-induced symptoms, reduced mortality, and mitigated muscle damage.
Conclusions:
- Deferoxamine demonstrates immunomodulatory effects by compensating for EV71-induced B cell reduction.
- Deferoxamine shows promise as a potential therapeutic agent for Enterovirus 71 infections.
- Further development of deferoxamine as a B cell-immunomodulator against EV71 is warranted.
More Related Videos
04:01Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
08:22Retroviral Overexpression of CXCR4 on Murine B-1a Cells and Adoptive Transfer for Targeted B-1a Cell Migration to the Bone Marrow and IgM Production
Published on: May 31, 2020